Kufril Syrup is a combination expectorant and bronchodilator formulation containing Ambroxol (15mg/5ml), Guaifenesin (50mg/5ml), and Terbutaline (1.25mg/5ml). Ambroxol acts as a mucolytic agent, facilitating the breakdown and clearance of mucus in the respiratory tract, thereby improving airway patency. Guaifenesin serves as an expectorant, promoting the loosening and thinning of mucus to enhance productive cough and facilitate expectoration. Terbutaline, a selective beta-2 adrenergic receptor agonist, provides bronchodilation by relaxing the smooth muscles of the airways, thus alleviating bronchospasm and improving airflow. Kufril Syrup is indicated for the symptomatic treatment of respiratory conditions characterized by excessive or thickened mucus production and bronchoconstriction, such as chronic bronchitis, asthma, and other obstructive airway diseases. The combined pharmacological actions of its active ingredients help reduce cough severity, improve mucus clearance, and relieve bronchospasm, contributing to enhanced respiratory function and patient comfort. Kufril Syrup should be used under medical supervision, with dosage adjusted according to age, severity of symptoms, and clinical response. Caution is advised in patients with cardiovascular disorders, hyperthyroidism, or hypersensitivity to any component.